Stockscreener 앱 받기
11.50
2.38%
-0.28
시간 외 거래:
12.00
0.50
+4.35%
전일 마감가:
$11.78
열려 있는:
$11.7
하루 거래량:
1.55M
Relative Volume:
0.44
시가총액:
$1.53B
수익:
-
순이익/손실:
$-766.97M
주가수익비율:
-1.5013
EPS:
-7.66
순현금흐름:
$-646.43M
1주 성능:
+6.88%
1개월 성능:
-2.87%
6개월 성능:
-14.63%
1년 성능:
-72.70%
1일 변동 폭
$11.37
$11.90
1주일 범위
$11.02
$13.08
52주 변동 폭
$7.48
$42.82
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
11.50 | 1.56B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-06 | 개시 | Goldman | Buy |
| 2026-01-21 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-06 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 개시 | Citigroup | Buy |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
(BHVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Assessing Biohaven (BHVN) Valuation As Analyst Optimism And Earnings Estimates Improve - simplywall.st
RSI Check: Can Biohaven Ltd deliver alpha2025 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Biohaven Ltd. (BHVN): Analyst Consensus Points to 63% Upside Potential Amidst Biotech Innovation - DirectorsTalk Interviews
Big Money Moves: What are analysts price targets for Biohaven LtdWall Street Watch & Detailed Earnings Play Strategies - baoquankhu1.vn
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Biohaven (NYSE:BHVN) Stock Price Up 8.4%Should You Buy? - MarketBeat
Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect? - Finviz
Goldman Sachs initiates coverage on Biohaven Pharma stock with Buy rating - Investing.com Australia
Published on: 2026-02-06 01:35:19 - baoquankhu1.vn
Breakout Zone: What are analysts price targets for Biohaven LtdPortfolio Update Report & Smart Investment Allocation Insights - baoquankhu1.vn
Biohaven Ltd. (BHVN) Stock Analysis: Exploring A 77% Potential Upside For Investors - DirectorsTalk Interviews
Price-Driven Insight from (BHVN) for Rule-Based Strategy - Stock Traders Daily
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Closing: Can Biohaven Ltd be recession proofWeekly Market Outlook & AI Driven Price Forecasts - baoquankhu1.vn
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 63% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Aug Action: Is First Merchants Corporation attractive for institutional investorsEarnings Risk Summary & Real-Time Volume Triggers - baoquankhu1.vn
Jim Cramer on Biohaven: “The Stock Seems Very Low to Me” - MSN
Assessing Biohaven (BHVN) Valuation After A Sharp Momentum Rebound - Yahoo Finance
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
This Albemarle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
RBC Capital Upgrades Biohaven (BHVN) - Nasdaq
BHVN Upgraded by RBC Capital: New Price Target of $22 | BHVN Sto - GuruFocus
RBC Upgrades Biohaven to Outperform From Sector Perform, Boosts Price Target to $22 From $9, Keeps Speculative Risk - marketscreener.com
Biohaven stock rating upgraded by RBC Capital on promising CNS data - Investing.com South Africa
(BHVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Biohaven (BHVN) Is Up 15.6% After Showcasing MoDE and TRAP Degrader Data in Autoimmune Diseases - simplywall.st
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly - BioSpace
Assessing Biohaven (BHVN) Valuation After Positive MoDE And TRAP Degrader Clinical Updates - simplywall.st
Pomerantz To Lead Biohaven Investors' FDA Approval Suit - Law360
Biohaven (NYSE:BHVN) Stock Price Up 8%Still a Buy? - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data - intellectia.ai
Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know - Benzinga
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - stocktitan.net
Can Biohaven Ltd. deliver alphaMarket Weekly Review & Low Risk High Reward Ideas - bollywoodhelpline.com
Biohaven Ltd. (BHVN) Investor Outlook: Navigating Opportunities with a 68% Upside Potential - DirectorsTalk Interviews
Biohaven (NYSE:BHVN) Shares Down 6.3%Here's Why - MarketBeat
Biohaven (BHVN) Is Up 19.2% After Early Success With Selective Antibody Degraders In Kidney, Thyroid Diseases - simplywall.st
Biohaven stock maintains Outperform rating at Baird on promising IgAN data - Investing.com
Biohaven stock maintains Outperform rating at Baird on promising IgAN data By Investing.com - Investing.com South Africa
Biohaven highlights degrader platforms in new investor presentation - TipRanks
Biohaven Ltd Announces Investor Presentation on January 12, 2026 - TradingView
Biohaven reports early patient data from protein degrader programs - StreetInsider
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Early trial data hint at new options for kidney disease, thyroid, seizures - Stock Titan
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - PR Newswire
Aug Update: Is Biohaven Ltd stock oversold or undervaluedJuly 2025 Volume & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Biohaven Ltd. (BHVN) upgraded to buy: Here's what you should know - MSN
(BHVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jobs Data: Why Biohaven Ltd stock attracts global investorsWeekly Stock Recap & AI Based Buy/Sell Signal Reports - moha.gov.vn
Volatility Watch: Why Biohaven Ltd stock attracts global investorsEarnings Growth Summary & Real-Time Volume Triggers - moha.gov.vn
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):